Lipigon acquires antisense drug candidates for cardiovascular and metabolic diseases from Secarna

Updated: May 14, 2020

“We are very pleased with the Secarna collaboration under the target validation agreement. Together we have built a strong patent portfolio and moreover, we have generated a powerful in vivo and in vitro data package. Secarna’s impressive LNAplusTM platform has given us fully optimized clinical candidates that we are looking forward to bringing into IND-enabling studies.” says CEO and co-founder Stefan K. Nilsson. “The acquisition is in line with Lipigon’s business model to fully control our pipeline until out-licensing or market introduction. We believe that this agreement will make our case more attractive for investors”.

Read full press release below.

PR Lipigon Secarna March 23rd 2020
Download PDF • 139KB